Background The incidence of adenocarcinomas of the distal esophagus, gastroesophageal junction (GEJ), and stomach diagnosed before age 50 years is increasing and early-onset disease may have a distinct phenotype. A comprehensive synthesis of clinicopathological and molecular differences between early-onset and average-...
F. Petrelli, L. Dottorini, S. Cherri et al.· ESMO gastrointestinal oncolo...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved from proof of concept to randomized clinical benefit: in previously treated metastatic PDAC, daraxonrasib improved median overall survival, p...
F. Petrelli, L. Dottorini, A. Zaniboni· Cancer· 0 citations
Uniform timing definitions, an explicit hierarchy separating direct evidence from extrapolation, and tumor-specific rather than universal rules for checkpoint inhibitor re-exposure are proposed for checkpoint inhibitor re-exposure.
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
F. Petrelli, Lara Colombo Zefinetti, A. D'Alessio et al.· Current Oncology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
